AUS
NZ
UK
CA
USA
IND
Summary Points
- The Australian healthcare sector displays positive trends post-FY24 reporting, with rising revenue and margins among ASX-listed firms.
- Companies like ResMed and CSL are gaining momentum, though challenges remain in pathology and aged care.
- Investment in technology and AI is increasing, with Ramsay Health Care and Sonic Healthcare at the forefront.
The recent FY24 reporting season has unveiled a more optimistic outlook for the Australian healthcare sector, with many ASX-listed companies displaying consistent revenue growth and improved profit margins. After navigating through the challenges posed by the pandemic, it appears that several healthcare firms are finding their footing again.
Cost-cutting measures have played a significant role in strengthening margins, although not all companies have experienced a resurgence in pricing power, according to a report from Jarden Research. Despite some improvement, staffing issues, particularly nursing shortages, continue to pose challenges in hospitals. The pathology sector faces high fixed costs and declining patient volumes, making recovery difficult. Aged care providers are also grappling with staffing challenges and new regulations that require increased care minutes per resident.
Nevertheless, a notable theme emerging from the reporting season is that many healthcare companies are rebounding after the tough times of the pandemic.
Highlights from Leading Healthcare Companies
ResMed (ASX:RMD) has notably improved its profit margins, which surged to an impressive 59% last quarter, even amid rising shipping costs. CSL (ASX:CSL) is also on a recovery path, witnessing a 1.2% increase in its margins.
However, the pathology sector is still feeling the effects of low patient numbers, compounded by a loss of higher-paying tests, hindering its ability to recover effectively.
Amidst these challenges, many healthcare companies are ramping up investment in technology and artificial intelligence. For instance, Ramsay Health Care (ASX:RHC) is committing significant resources to digital transformation, while Sonic Healthcare (ASX:SHL) is leading in AI innovation, particularly in pathology and radiology, with new platforms poised to revolutionize operations.
Jarden's Stock Insights
Jarden has highlighted two ASX healthcare companies worth monitoring closely:
Telix Pharma (ASX:TLX) has garnered strong interest, despite a mixed bag of financial results for the first half of 2024. The company missed its profit target by 18% due to unexpected costs related to recent acquisitions, a common occurrence in the expansion phase. However, Telix remains optimistic, maintaining its revenue forecast between $745 million and $776 million for the year. A significant boost to its confidence stems from raising $650 million through convertible bonds, allowing for further investments in research and development. Telix is focused on expanding its market share with Illucix, an imaging product for cancer, and is eyeing opportunities in Brazil, which could represent 30-40% of its sales outside the U.S. Additionally, Telix is exploring the expansion of existing products and looking into mergers and acquisitions to enhance its research capabilities.
CSL received an Overweight rating from Jarden, with a target price of $329.62 over the next 12 months. Despite some recent fluctuations, CSL delivered strong numbers that met the high end of its profit guidance for FY24. The company’s Behring division, which specializes in therapies derived from human blood plasma, has significant growth potential, with Jarden projecting an 830 basis point (8.3%) gross margin boost driven by an anticipated revenue of $13.5 billion. The introduction of new technologies, such as the Rika plasmapheresis device, aims to enhance plasma yield and reduce costs. Excitement surrounds new high-margin products, including Hemgenix and Garadacimab, further indicating CSL's potential return to pre-COVID margin levels.
The Australian healthcare sector is demonstrating promising recovery signs as ASX-listed companies adapt to post-pandemic realities. While some challenges remain, particularly in the pathology and aged care sectors, companies like ResMed and CSL are paving the way for growth. With increasing investments in technology and AI, the future looks bright for healthcare businesses looking to capitalize on evolving market dynamics.
